Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 25, Issue 2, Pages 97-106

K-RAS and P53 Mutations in Association with COX-2 and Htert Expression and Clinico-Pathological Status of Nsclc Patients

Mojca Stražišar, Tomaž Rott, and Damjan Glavač

Department of Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Received 8 October 2008; Accepted 8 October 2008

Copyright © 2008 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We evaluated the occurrence of mutations in P53, K-RAS, COX-2, expression of COX-2 and hTERT and relations among clinicopathological signs. P53 mutations were identified in 34.4% of tumours, the majority of them occurring in SCC (squamous cell carcinoma, 55.6%). K-RAS was mutated in 12.2% of NSCLC tumours, the majority of the mutations being found in ADC (adenocarcinoma, 27.0%). Mutational screening detected three different COX-2 mutations and five different P53 mutations, published for the first time. With RT-PCR we observed that the expression of the tested genes, hTERT and COX-2, was highly significant for ADC (p < 0.01) and SCC (p < 0.05). Statistical analysis of the combined results revealed significant correlation between expression of COX-2 and hTERT (p < 0.001), hTERT expression and staging (p < 0.05) and survival (p < 0.01). A positive correlation between COX-2 expression and K-RAS mutation (p <0.05) was also observed. This study provides insight into associations between the analysed biomarkers and the clinical-pathological data of the patients.